Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2007

View Archived Issues

Recent Bayer patents report novel therapeutic agents for urological disorders

New agents for treating neurological disorders disclosed in recent patent literature

New therapeutic strategies for cancer imparted in recent patents

BENCHMRK studies reveal activity of raltegravir in triple-class resistant HIV

Interleukin-12 gene therapy safe in phase I ovarian cancer study

Maraviroc effective in phase IIb/III studies in CCR5-tropic HIV-1

rAAV HIV vaccine safe, well tolerated in healthy subjects

Entecavir selects for HIV resistance mutations

Idenix develops potent and selective anti-HIV agents

Treatment complete in phase II osteoarthritis study of Indaflex

MIV-701 begins clinical studies for osteoporosis

Novartis Consumer Health to copromote Vusion ointment to U.S. pediatricians

Encouraging proof-of-concept results for PA-325

Enrollment complete in phase I/II study of ALKS-29 in alcohol dependence

Financing at TransOral to support Intermezzo NDA filing

Enrollment completed in phase II study of CTA-018 for psoriasis

Sinovac updates progress of pandemic influenza vaccine study

Sunesis studies SNS-032 for advanced B-cell malignancies in clinic

Phase II study of faropenem in acute otitis media meets primary objective

Panzem NCD studied with Sutent in metastatic renal cell carcinoma

Roche's HPV tests accepted for FDA review

Enrollment completed in phase IIb study of AeroLEF

Sankyo and Biota license Hovione's inhaler technology for influenza

Amarin acquires rights to nasal lorazepam for emergency epilepsy seizures

Target enrollment reached in phase III trials of Puricase

Flurizan shows benefit in mild Alzheimer's patients

Topline MERLIN TIMI-36 results for ranolazine

Moli-1901 improves lung function in cystic fibrosis study

Lipitor approved for five new indications in heart disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...